A New Jersey federal judge on Thursday certified a group of Becton Dickinson & Co. investors who accused the medical technology maker of hiding looming regulatory hurdles impacting sales of its Alaris infusion pump, finding the investors have shown that the question of individual damages calculations won't overwhelm common questions affecting the class.